Claims
- 1. A pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C.sub.13 H.sub.16 O.sub.8 N.sub.2 S.sub.2 which in the form of a substantially pure sodium salt has the following characteristics:
- (a) in aqueous solution, it has a characteristic ultra violet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1;
- (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm.sup.-1 ;
- (c) it has a characteristic N.M.R. spectrum when taken in D.sub.2 O which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85.tau. and 4.00.tau. with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55.tau. and (iii) a sharp singlet at approximately 8.00.tau.;
- (d) it possesses antibacterial activity against various species including inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and
- (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russell.
- 2. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of an alkali metal salt.
- 3. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of the sodium, potassium, calcium, magnesium, aluminium or ammonium salt.
- 4. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of the di-sodium salt.
- 5. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 in the form of the di-potassium salt.
- 6. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 which is at least 70% pure.
- 7. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 which is at least 80% pure.
- 8. A pharmaceutically acceptable di-basic salt of MM 13902 according to claim 1 which is 90%-100% pure.
- 9. A process for the preparation of substantially pure MM 13902 in the form of a pharmaceutically acceptable di-basic salt wherein MM 13902 is a solid carboxylic acid of the molecular formula C.sub.13 H.sub.16 O.sub.8 N.sub.2 S.sub.2 which in the form of a substantially pure sodium salt has the following characteristics:
- (a) in aqueous solution, it has a characteristic ultraviolet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1;
- (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm.sup.-1 ;
- (c) it has a characteristic N.M.R. spectrum when taken in D.sub.2 O, which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85.tau. and 4.00.tau. with coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55.tau. and (iii) a sharp singlet at approximately 8.00.tau.;
- (d) it possesses antibacterial activity against various species including inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and
- (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russel;
- which comprises cultivating a MM 13902 producing strain of Streptomyces olivaceus having the same identifying characteristics as ATCC 31126 in a suitable medium containing an assimilable source of carbon, hydrogen and nitrogen until a significant amount of antibiotic activity has been imparted to said medium and recovering the substantially pure, pharmaceutically acceptable di-basic salt of MM 13902 from the culture medium.
- 10. A process according to claim 9 for the preparation of substantially pure MM 13902 in the form of a pharmaceutically acceptable di-sodium or di-potassium salt wherein the substantially pure, pharmaceutically acceptable salt of MM 13902 is recovered as a di-sodium or di-potassium salt.
Priority Claims (1)
Number |
Date |
Country |
Kind |
13856/74 |
Mar 1974 |
GB |
|
CROSS REFERENCE
This application is a continuation-in-part of U.S. Patent Application Ser. No. 559,803 filed Mar. 19, 1975 now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3919415 |
Butterworth et al. |
Nov 1975 |
|
3950357 |
Kahan et al. |
Apr 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
559803 |
Mar 1975 |
|